StockData

Niki BioSolutions, Inc. (NIKI) stock

NIKINasdaqMeasuring & Controlling Devices, NECFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 4/30
$1.50−0.20 (-11.76%)

Close on Nov 17, 2026Market cap $12.22MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025

Valuation

Market cap
$12.22M
P/E ratio
–
Price to sales
–
Price to book
0.53
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$1.36M
EPS, diluted
-$0.19
Book value per share
$2.89
Diluted shares
8M

Trading

Previous close
$1.70
Open
$1.71
Day's range
$1.50 – $1.71
Volume
6,381
Average volume (20 days)
20,672
52-week range
$1.42 – $17.20
RSI (14 days)
29.1
Volatility (1 year)
100.5%
Relative volume
0.05×

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodNIKIS&P 500DifferenceNIKI per yearS&P 500 per year
1 month-26.1%-4.0%−22.1 pts
3 months-81.8%-5.0%−76.9 pts
Year to date-85.8%+8.2%−94.1 pts
1 year-88.9%+11.2%−100.1 pts
3 years-91.1%+68.5%−159.5 pts-55.3%+19.0%
5 years-99.3%+67.3%−166.6 pts-62.9%+10.8%

Nine years at a glance

Fiscal years 2017 to 2025, USD

Revenue

–

Gross profit

–

Net income

-$1.36M

EPS, diluted

-$0.19

Free cash flow

–
Reported period

Press releases

Releases Niki BioSolutions filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Niki BioSolutions

Measuring & Controlling Devices, NEC

Aptorum Group Limited is a clinical-stage biopharmaceutical enterprise focused on researching, developing, and commercializing novel therapeutic drug candidates and healthcare solutions. Its primary development pipeline centers on preclinical and clinical drug assets, including its lead projects ALS-4 and SACT-1, with SACT-1 targeted as a pediatric formulation for neuroblastoma. In addition to pharmaceutical drug candidates, the organization previously engaged in healthcare service operations through an outpatient medical clinic known as Talem Medical, serving individual clinical patients via employed physicians.

Company profile, executives and history

Niki BioSolutions stock: common questions

What is Niki BioSolutions's stock price?

NIKI closed at $1.50 on Nov 17, 2026, down 11.76% on the day. Over the past 52 weeks it traded between $1.42 and $17.20.

What is Niki BioSolutions's market cap?

Niki BioSolutions was worth $12.22M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is NIKI's P/E ratio?

Niki BioSolutions lost money over the twelve months to Dec 31, 2025 (diluted EPS -$0.19), so it has no meaningful P/E ratio.

Does Niki BioSolutions pay a dividend?

No. Niki BioSolutions has not paid a cash dividend over the last twelve months.

How has NIKI stock performed over the past year?

Including dividends, NIKI returned -88.9% over the past year, against +11.2% for the S&P 500.

How many NIKI shares are sold short?

0M shares were sold short at the latest FINRA report, 0.03% of the float, or 1.0 days of average trading volume.

Who are Niki BioSolutions's competitors?

Companies most similar to Niki BioSolutions by business, industry and size include QSI, TMO, MIR, HBIO, EYPT.

See a number that looks wrong?